Compare KB Financial Group, Inc. (KB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? KB Financial Group, Inc. trades at $122.97 (market cap $42.62B), while Vertex Pharmaceuticals Incorporated trades at $511.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KB | VRTX | |
|---|---|---|
Market Cap | $42.62B | $127.55B |
Volume | 164,291 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $132.88 | $557.96 |
52-Week Low | $77.50 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $215.53T | $121.68B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $122.78, down 1.56% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with consistent earnings beats, growing revenue from $21.23T to $22.37T projected for 2026, and improving profit margins reaching 28.09%. Recent analyst coverage shows 33% buy ratings with positive momentum commentary from multiple financial outlets.
The outlook remains positive given KB's attractive valuation at 9.68 P/E and 0.94 P/B, coupled with sustained earnings growth. Key risks include market volatility and the company's significant investment outflows. Analyst consensus leans neutral with 67% hold ratings, suggesting cautious optimism for this value-oriented financial stock.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
